In a conversation with Nicole Raliegh on the Pharmaphorum podcast, Bobby Savarese, Senior Principal, Unispace Life Sciences shares his thoughts on trends like sustainability and technology influencing the life sciences sector, and space design.
What are blue chip pharma companies focusing on?
In our Global Life Sciences Benchmarking report, Forefront, we surveyed and interviewed over 180 life sciences leaders to learn about practices and trends influencingin the industry. What we found was engineering and research teams have readapted their primary goals based on what happened during and post-pandemic.Among the key areas of focus was sustainability.
How are companies meeting their sustainability initiatives?
56% of our survey respondents indicated having sustainability goals and implementation guidelines. The result is a pathway target of total carbon neutrality. This primarily will be achieved through three key areas:
Reducing carbon footprints
Conservation of water
Designing green buildings
How can the next generation laboratory set the pace for future innovation?
FutureLab considers the critical technologies needed in a laboratory. This includes:
Lab information management systems
Digital twin technology
Applied AI technology
Bio safety and cyber safety
Using quantum computers, we can unify these technologies and accelerate the R&D project life cycle and enable faster reliance recognition for new drug approval.
How does this impact laboratory design?
From our experience creating spaces to house quantum computers, we’ve found it’s critical to implement the right facility requirements like heating and cooling systems, clean room space, and specific flooring. Architectural features like ceiling height also need to adapt to host the quantum computers.
How does this optimize lab space requirements?
One of the key goals of FutureLab is reducing space per R&D specialist by 2 sqm. We can achieve this through:
Optimizing flexible space allocation
Integrating technologies within an open space environment to create collaborative collision courses
Creating regulated concierge service delivery
How have labs evolved?
The post-pandemic era has encouraged us and life sciences companies to look for ways to improve processes and drug discovery while maintaining the status quo. FutureLab will enable companies to reduce their square footage but more importantly be more efficient and socially engaged. By using technologies to get into a faster reliance recognition, we’re creating a harmony of bringing different groups of people together to accelerate drug approvals for many of the diseases out there.
Bobby Savarese, Senior Principal, Life Sciences Bobby draws upon his experience in delivering end-to-end Design & Build solutions for our Life Science R&D partners. His previous roles included overseeing global key accounts within the Life Sciences sector, where he applied his expertise to deliver client-centric solutions. Bobby has also made contributions as the Vice President of a global Biotech Life Sciences company, driving innovation through the introduction of advanced technologies and championing the adoption of integrative modular solutions within the Life Sciences industry.